Consensus Spero Therapeutics, Inc.

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-10 EDT			5-day change	1st Jan Change
1.230 ^USD	-2.38%		+6.96%	-47.21%

07-27	Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer	CI
07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ

Evolution of the Average Target: Spero Therapeutics, Inc.

Evolution of the Target Price: Spero Therapeutics, Inc.

Changes in Analyst Recommendations: Spero Therapeutics, Inc.

808363a7fc0a20e22c549.VLn9Hry86tqIPAJXUJXqFq-6t4iBH5nHbmloedpN8t0.Ls21KfaJnqjZd3YyIuWsWefN9O7pQMGGV18SHqA5iuQO2IRJ0ciDkudmcQ~6f2c7fd687d6d4750a2524942450f49f

Analysts' recommendations: Spero Therapeutics, Inc.

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT
22-09-26	HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating	MT
22-09-22	Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line	MT
22-08-15	HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating	MT
22-07-01	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
22-05-23	HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating	MT
22-05-20	Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44	MT
22-05-17	Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept	MT
22-05-04	Cowen Downgrades Spero Therapeutics to Market Perform From Outperform	MT
22-05-04	Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40	MT
22-04-18	HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating	MT
22-03-21	HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating	MT
21-11-16	Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating	MT
21-10-01	SPERO THERAPEUTICS : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform	MT
21-03-12	SPERO THERAPEUTICS : Oppenheimer Adjusts Spero Therapeutics PT to $20 From $21, Maintains Outperform Rating	MT
21-01-22	SPERO THERAPEUTICS : HC Wainwright Adjusts Spero Therapeutics' Price Target to $40 From $33, Keeps at Buy	MT
21-01-05	SPERO THERAPEUTICS : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating	MT
20-12-16	SPERO THERAPEUTICS : Berenberg Starts Spero Therapeutics at Buy With $47 Price Target	MT
20-11-23	SPERO THERAPEUTICS : HC Wainwright Adjusts Price Target on Spero Therapeutics to $33 From $28, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
SPERO THERAPEUTICS, INC.	-	-	-	+225.2%
WUXI APPTEC CO., LTD.				+9.67%
ARGENX SE				+17.12%
INSMED INCORPORATED				+48.46%
WUXI BIOLOGICS (CAYMAN) INC.				+2.01%
BIONTECH SE				+29.88%
GENMAB A/S				+20.68%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				+7.31%
PHARMAESSENTIA CORPORATION				-19.3%
EXELIXIS, INC.				-0.04%
Average				+34.10%
Weighted average by Cap.				+14.90%